[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586347":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":35,"locations":41,"responsibleParty":54,"collaborators":57,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":34,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":34,"enrollmentInfo":75,"targetDuration":34,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":86,"whyStopped":34,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"esketamine group","EXPERIMENTAL","esketamine+PRF group",[13],"Drug: esketamine+PRF treatment group",{"label":15,"type":16,"description":17,"interventionNames":18},"control group","ACTIVE_COMPARATOR","PRF group",[19],"Drug: PRF treatment group",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","esketamine+PRF treatment group","In the esketamine group, in addition to receiving PRF treatment+pregabalin, patients will also undergo a single intravenous infusion of esketamine.",[9],[27],"esketamine+PRF treatment+pregabalin",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"PRF treatment group","In the control group, patients will receive PRF treatment. PRF will be performed on DRG by an designated physician in each participating center. The patients will be treated with PRF (PMG-230, Baylis Medical Inc.) using a 21-gauge sterilized radiofrequency needle (a 10-cm trocar with a 5-mm active tip, PMF-21-100-5, Baylis Medical Inc.), which will be carefully inserted until the needle tip reached the upper edge of the intervertebral foramen under the guidance of three-dimensional (3D) CT. PRF treatment (PMG-230, Baylis Medical Inc.) targeting to DRG will be applied for 900 seconds. The parameters of PRF treatment will be set at 42 ℃, 2 Hz with 20 milliseconds current. Regarding pregabalin, the dosage is titrated based on patients'pain intensity and tolerance. This process fully accounts for individual patient differences to optimize treatment outcomes.",[15],[33],"PRF treatment+pregabalin",null,[36],{"name":37,"role":38,"phone":39,"phoneExt":34,"email":40},"Fang Luo","CONTACT","+86 13611326978","13611326978@163.com",[42],{"facility":5,"status":34,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":34},"Beijing","Beijing Municipality","100070","China","CN",{"type":49,"coordinates":50},"Point",[51,52],116.39723,39.9075,{"lat":52,"lon":51},{"type":55,"investigatorFullName":37,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":34,"oldOrganization":34},"PRINCIPAL_INVESTIGATOR","Director of Department of Day surgery and Pain Management",[58,60,62,64],{"name":59,"class":6},"Beijing Xiaotangshan Hospital",{"name":61,"class":6},"The First Hospital of Fangshan District,Beijing",{"name":63,"class":6},"Beijing Ditan Hospital",{"name":65,"class":6},"Hengshui People's Hospital","100586347","esketamine-combined-with-prf-of-drg-for-postherpetic-neuralgia-100586347",false,"NCT06914193","Esketamine Combined With PRF of DRG for Postherpetic Neuralgia","Intravenous Infusion of Esketamine in Combination With Pulsed Radiofrequency of Dorsal Root Ganglion for Postherpetic Neuralgia","Inclusion Criteria:\n\n1. Ages more than 18 years;\n2. Pain persisting for over three months following the onset of the herpes zoster skin rash;\n3. Lesions located in in the unilateral cervical, thoracic, and lumbosacral segments;\n4. Having an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10= worst possible pain)； Planned to perform CT-guided PRF treatment of the Dorsal root ganglion（DRG）\n\nExclusion Criteria:\n\n1. Obstructive sleep apnoea syndrome;\n2. Those who receive other more invasive treatments, such as radiofrequency thermocoagulation (RFT) of DRG.\n3. A history of systemic immune diseases, organ transplantation, or cancers;\n4. A history of severe cardiopulmonary, hepatic, renal dysfunction or coagulation function disorder;\n5. A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;\n6. Comorbid hyperthyroidism or phaeochromocytoma;\n7. Recent history of drug abuse;\n8. Having contraindications to esketamine;\n9. Communication difficulties.\n10. Women who are preparing for pregnancy, in the pregnancy or lactation period.","ALL","18 Years",{"count":76,"type":77},186,"ESTIMATED","INTERVENTIONAL",[80],"NA","This trial's primary objective is to compare the analgesic efficacy of esketamine in combination with pulsed radiofrequency (PRF) of dorsal root ganglion(DRG) against that of PRF monotherapy in patients with postherpetic neuralgia(PHN).",[83],"Postherpetic Neuralgia",[83,85],"Esketamine","NOT_YET_RECRUITING","2025-04-05",{"date":89,"type":90},"2025-04-09","ACTUAL",{"date":92,"type":77},"2025-04-01",{"date":94,"type":77},"2026-10-01",{"name":5,"class":6},1]